Darmstadt, Germany (ots/PRNewswire) - Not intended for UK-based media ESMO Abstract # Avelumab: 777PD, 7775PD, 1154P, 842TiP, 844TiP; Erbitux: 527P, 491P, 967P, 994P; Tepotinib: 1257P, 1287TiP, 1292TiP - Merck KGaA, Darmstadt, Germany, to feature new research from marketed and pipeline compounds - Preliminary results from combination study with avelumab in renal cell ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK- or US-based media ESMO Abstract # Avelumab: 777PD, 775PD, 1154P, 842TiP, 844TiP; Erbitux: 527P, 491P, 967P, 994P; Tepotinib: 1257P, 1287TiP, 1292TiP - Merck to feature new research from marketed and pipeline compounds - Preliminary results from combination study with avelumab in renal cell carcinoma, and ...
Darmstadt, Germany (ots/PRNewswire) - - New partnership under Healthy Women, Healthy Economies initiative facilitates women to overcome health barriers to economic participation Merck, a leading science and technology company, today announced its partnership with the Royal Health Awareness Society (RHAS) of Jordan to advance health awareness and education particularly ...
Bagsværd, Denmark (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Novo Nordisk today announced that the Committee for Medicinal Products for Human Use, CHMP, has adopted a positive opinion to extend the use of NovoRapid® (insulin aspart) in the European Union for children with ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK-based media - Phase III studies highlight lasting reductions in relapse rates for an additional two years following short oral treatment courses in year one & year two with Cladribine Tablets Merck, a leading science and technology company, announced they ...
Munich (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Novo Nordisk today announced that semaglutide, an investigational glucagon-like peptide-1 (GLP-1) analogue administered once-weekly, significantly reduced the risk of the ...
Darmstadt, Germany (ots/PRNewswire) - - Four research grants awarded out of 260 proposals from 45 countries Merck, a leading science and technology company, today announced recipients of the fourth annual Grant for Multiple Sclerosis Innovation (GMSI) during a symposium at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis ...
Munich (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Novo Nordisk today announced that the progression of kidney damage was significantly lower with Victoza® treatment vs placebo, as measured by urinary albumin creatinine ratio, both added to standard of care in 9,340 adults ...
Paris (ots/PRNewswire) - Further comparative data expected from ongoing head-to-head clinical trial Sanofi (http://www.sanofi.com) announced today the key results of a new pharmacokinetic / pharmacodynamic (PK/PD) study in people with type 1 diabetes comparing Toujeo® (insulin glargine 300 Units/mL) to insulin ...
Munich (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Results from a post hoc analysis of the three-year part of the phase 3a SCALE (Satiety and Clinical Adiposity - Liraglutide Evidence) Obesity and Prediabetes trial show ...
Paris (ots/PRNewswire) - - Benefits on adherence and HbA1c to be validated in a real-world setting - Sanofi (http://www.sanofi.com) announced today that adults with type 2 diabetes treated with Toujeo® (insulin glargine 300 Units/mL) experienced a consistently lower rate of confirmed or severe hypoglycemia both at ...
Munich, Germany (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Novo Nordisk today presented data showing the odds of reaching fasting plasma glucose (FPG) targets without hypoglycaemia and weight gain were significantly ...
Munich (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Novo Nordisk today announced that semaglutide, an investigational glucagon-like peptide-1 (GLP-1) analogue administered once-weekly, significantly improved glycaemic ...
Darmstadt, Germany (ots/PRNewswire) - - Two oral presentations and nine posters include new analyses on investigational Cladribine Tablets - Real-world data assess the safety, tolerability and effectiveness of Rebif® - Symposium highlights unmet needs among patients with MS and real-word issues - Grant for Multiple ...
Verona, Italy (ots/PRNewswire) - CROMSOURCE, an international contract research organization (CRO) providing a comprehensive portfolio of services to the pharmaceutical, biotechnology, and medical device industries, announced today the appointment of its new Chief Medical Officer, Dr. Grzegorz Rychlik, and the expansion of its Medical Affairs Services department. ...
Amsterdam and London (ots/PRNewswire) - Philips to highlight the Dream Family connected therapy system, announcing its extension with the introduction of BiPAP autoSV and BiPAP AVAPS therapy devices Philips Respironics (http://www.respironics.com/), a division of Royal Philips (http://www.usa.philips.com/) (NYSE: ...
Munich (ots/PRNewswire) - Not for US or UK media - ENSURE-AF is the largest clinical trial of a non-vitamin K antagonist oral anticoagulant in patients with non-valvular atrial fibrillation - who undergo electrical cardioversion - ENSURE-AF is a Prospective, Randomized, Open-Label, Blinded E ndpoint evaluation ...
Calgary, Alberta (ots/PRNewswire) - The presentations at the ESC Congress symposium highlighted apabetalone and the opportunity and need for a novel approach to the treatment of high risk cardiovascular disease and diabetes. Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) today announced that on Sunday, ...
Shire Pharmaceuticals Group Plc
Lexington, Massachusetts (ots/PRNewswire) - - Xiidra is the only prescription eye drop approved by the U.S. FDA for the treatment of both signs and symptoms of dry eye disease - Resources are available to support patients seeking information regarding coverage and savings offers - Xiidra is the first medication in a ...
Munich (ots/PRNewswire) - Sub-analysis data from atrial fibrillation patient registry sponsored by Daiichi Sankyo reveals at-risk patient groups and recent trends in disease management[1],[2] Not for US media Daiichi Sankyo Europe GmbH (hereafter, Daiichi Sankyo) today announced data from new sub-analyses of the ...
Shire Pharmaceuticals Group Plc
Lexington, Massachusetts (ots/PRNewswire) - Jennifer Aniston Opens Up about Personal Experience with Dry Eye Symptoms, Which Have Been Reported by Nearly 30 Million Americans Jennifer Aniston is one of the millions of Americans who experience symptoms consistent with Chronic Dry Eye. Commonly referred to as Dry Eye, ...
Munich (ots/PRNewswire) - - ENSURE-AF results to be featured during a late-breaking clinical trial session - Five abstracts highlighting analyses from the global phase 3 ENGAGE AF-TIMI 48 study to be presented - Seven abstracts to reveal new findings from the PREFER in AF and VTE European patient registries Daiichi ...
Kanata, Ontario (ots/PRNewswire) - Agreement Highlights - Purchase agreement covers REVISS Services (UK) Ltd. and subsidiary REVISS Services Inc. (USA) - REVISS had ceased trading in cobalt-60 in April 2014 - REVISS Services will be integrated into the operations of Nordion (Canada) Inc. - Acquisition allows Nordion ...
London (ots/PRNewswire) - ViiV Healthcare today announced the start of a phase III programme to support regulatory filings for a two-drug regimen of dolutegravir (Tivicay®) and lamivudine (Epivir®) as a treatment for HIV-1 infection in adults who have not received prior antiretroviral therapy. (Logo: ...
Stockholm (ots/PRNewswire) - Mr Costa, currently CEO of Nordic Nanovector ASA, a biotech company focused on the development of innovative treatments in hematology and oncology, brings to Oncopeptides more than 20 years' experience in the international pharmaceutical and biotech industry. Prior to his current position, he was Vice President of Europe, Middle East and Africa for Onyx Pharmaceuticals Inc. where he led the ...
Calgary, Alberta (ots/PRNewswire) - A data review by the independent Data Safety Monitoring Board resulted in a verbal recommendation for the BETonMACE trial to continue as planned without any modification. Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) today announced that the independent Data and ...
Sunnyvale, California (ots/PRNewswire) - Next Generation Image-Guided Radiation Therapy Platform and Integrated Software Solutions are Now Available for Use by Clinicians in the European Union Accuray Incorporated (NASDAQ: ARAY) announced today that it has CE marked its Radixact(TM) Treatment Delivery System, Accuray Precision(TM) Treatment Planning System and iDMS(TM) Data Management System. The next generation hardware ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK- or US-based media - Liquid biopsy RAS biomarker test based upon AmoyDx's real-time PCR technology, ADx-SuperARMS®, will be made available in China in 2017 - Merck is the first pharmaceutical company to collaborate with multiple diagnostic providers to support liquid biopsy RAS biomarker testing worldwide ...
Aberdeen, Scotland and Singapore (ots/PRNewswire) - Promising Read-Out for First-Ever Tau Aggregation Inhibitor to Enter Phase 3 Trials - LMTX® as monotherapy demonstrates significant reductions in disease progression in mild and moderate Alzheimer's disease - Strong results in both cognitive and functional tests supported by brain scan evidence of slow-down in progression of pathology - Study misses co-primary endpoints ...
Shire Pharmaceuticals Group Plc
Zug, Switzerland (ots/PRNewswire) - The positive opinion is based on a pivotal Phase 3 study showing that ONIVYDE combined with chemotherapy significantly increased overall survival (OS) in patients with metastatic pancreatic cancer after previous gemcitabine based therapy Shire plc (LSE: SHP, NASDAQ: SHPG) today ...